This is a working overview of wound model, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Many researchers proposed that at the physiological pH, GHK-Cu complexes can form binary and ternary structures which may involve amino acid histidine and/or the copper binding region of the albumin molecule. Lau and Sarkar found also that GHK can easily obtain copper 2+ bound to other molecules such as the high affinity copper transport site on plasma albumin (albumin binding constant log 10 =16.2 vs. GHK binding constant 16 log 10 =16.44). It has been established that copper (II) redox activity is silenced when copper ions are complexed with the GHK tripeptide, which allows the delivery of non-toxic copper into the cell.
== Chemical reactions == Its acid–base properties are most important. In aqueous solution, glycine is amphoteric: below pH = 2.4, it converts to the ammonium cation called glycinium. Above about pH 9.6, it converts to glycinate.
The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the import of nitrate, nitrite, and cyanate. ATP + H2O + nitrate [nitrate - binding protein][side 1] = ADP + phosphate + nitrate [side 2] + [nitrate - binding protein][side 1] 7.3.2.5 ABC-type molybdate transporter The expected taxonomic range for this enzyme is: Archaea, Eukaryota, Bacteria. The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the high-affinity import of molybdate and tungstate. Does not undergo phosphorylation during the transport process. ATP + H2O + molybdate [molybdate - binding protein][side 1] = ADP + phosphate + molybdate [side 2] + [molybdate - binding protein][side 1] 7.3.2.6 ABC-type tungstate transporter The expected taxonomic range for this enzyme is: Archaea, Bacteria. The enzyme, characterized from the archaeon Pyrococcus furiosus, the Gram-positive bacterium Peptoclostridium acidaminophilum (Eubacterium acidaminophilum) and the Gram-negative bacterium Campylobacter jejuni, interacts with an extracytoplasmic substrate binding protein and mediates the import of tungstate into the cell for incorporation into tungsten-dependent enzymes. ATP + H2O + tungstate [tungstate - binding protein][side 1] = ADP + phosphate + tungstate [side 2] + [tungstate - binding protein][side 1]
==== Ban ==== Banban Akaza (赤座 伴番, Akaza Banban), also known as "Ban" (バン), is a hot-headed, chaotic, loudmouthed, bad-tempered, yet fiercely loyal and friendly rookie member of the S.P.D., who previously trained in space before being assigned to lead S.P.D.'s Earth unit in the field as Deka Red (デカレッド, Deka Reddo). While he joins the newly created Fire Squad as an elite officer in the series finale, he occasionally returns to help his original team. Initially having an immature personality, he slowly matures throughout the series. In battle, Ban is a practitioner of the space martial art Juu Kune Do (ジュウクンドー, Jū Kun Dō), which blends unarmed martial arts skills with gunplay. As Deka Red, he dual wields a pair of D-Magnum (ディーマグナム, Dī Magunamu) rayguns, which can combine to form the Hybrid Magnum (ハイブリッドマグナム, Haiburiddo Magunamu) shotgun and allow him to perform the Magnum Execution (マグナムエクスキュージョン, Magunamu Ekusukyūjon), Moonsault Shot (ムーンサルトショット, Mūnsaruto Shotto), Endless Shot (エンドレスショット, Endoresu Shotto), Hurricane Shot (ハリケーンショット, Harikēn Shotto), and Moonsault Galaxy Shot (ムーンサルトギャラクシーショット, Mūnsaruto Gyarakushī Shotto) attacks. He also shares riding the Machine Doberman (マシンドーベルマン, Mashin Dōberuman) police car with Jasmine. If necessary, he can borrow Doggie Kruger's D-Sword Vega to perform the Akaza Sword Art: Raijin Sword (赤座剣法・雷神剣, Akaza Kenpō Raijin Ken) and Impulse Vega Slash (インパルスベガスラッシュ, Inparusu Bega Surasshu) attacks. During the events of the crossover film Mahō Sentai Magiranger vs.
Sources: en.wikipedia.org
=== Cholecystitis === Total parenteral nutrition increases the risk of acute cholecystitis due to complete disuse of the gastrointestinal tract, which may result in bile stasis in the gallbladder. Other potential hepatobiliary dysfunctions include steatosis, steatohepatitis, cholestasis, and cholelithiasis. Six percent of patients on TPN longer than three weeks and 100% of patients on TPN longer than 13 weeks develop biliary sludge. The formation of sludge is the result of stasis due to lack of enteric stimulation and is not due to changes in bile composition. Gallbladder sludge disappears after four weeks of a normal oral diet. Administration of exogenous cholecystokinin (CCK) or stimulation of endogenous CCK by a periodic pulse of large amounts of amino acids has been shown to help prevent sludge formation. These therapies are not routinely recommended. Such complications are suggested to be the main reason for mortality in people requiring long-term total parenteral nutrition, such as in short bowel syndrome. In newborn infants with short bowel syndrome with less than 10% of expected intestinal length, thereby being dependent upon total parenteral nutrition, five-year survival is approximately 20%.
Because metro stations outside Moscow's city center are spaced relatively far apart from each other—up to 4 kilometers (2.5 mi)—compared to other cities, a radial bus network connects each station to the surrounding residential zones. Moscow has a bus terminal (the Central Bus Terminal) for long-range and intercity passenger buses, handling about 25 thousand passengers each day and serving about 40% of long-range bus routes in Moscow. Every major street in Moscow is served by at least one bus route. Many of these routes share a trolleybus route and have overhead trolley wires. The Moscow trolleybus system has a total line length of almost 600 kilometers (370 mi) of single wires, 8 depots, 104 routes, and 1740 vehicles; this system was the world's largest. However, the municipal authority, headed by Sergey Sobyanin, began to phase out the trolleybus system in 2014 because of its planned replacement with electric buses. In 2018, the trolleybus system retained only 4 depots and dozens of kilometers of unused overhead wires. Almost all wires inside the Garden Ring (Sadovoe Koltso) were cut in 2016–2017 because the central streets were rebuilt (the "Moya Ulitsa" project). Opened on 15 November 1933, Moscow's trolleybus system is the world's sixth-oldest such system in operation. In 2018, the vehicle companies Kamaz and GAZ won the Mosgortrans contract to deliver 200 electric buses and 62 ultrafast charging stations for the city's transport system. The manufacturers are responsible for the quality and reliable operation of buses and charging stations for 15 years.
Ren H, Han R, Chen X, Liu X, Wan J, Wang L, Yang X, Wang J (May 2020). "Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update". J Cereb Blood Flow Metab. 40 (9): 1752–68. doi:10.1177/0271678X20923551. PMC 7446569. PMID 32423330.
Sources: en.wikipedia.org
=== Phase 2 === Acetylcysteine lysinate (L-lysine-N-acetyl-L-cysteinate; N-acetylcysteine lysinate; Nacystelyn) – antioxidant Aminolevulinic acid (ALA; BF-200 ALA) – photosensitizer Cannabidiol topical (CBD; BTX-1204; BTX-1308; BTX-1503; BTX-1702; BTX-1801; PBX-1308) – cannabinoid Dimethylcurcumin (ASCJ-9; AJ-101; ASC-J9) – androgen receptor degradation enhancer Imsidolimab (ANB-019) – monoclonal antibody against the interleukin-36 receptor Ivermectin topical (CD-5024; Soolantra) – non-mammalian chloride channel opener LYS-006 – leukotriene A4 hydrolase (LTA4H) inhibitor Methyl aminolevulinate (MAL; CD06809-41; Luxerm; MAL-PDT; Metvix; Metvixia; P-1202; Visonac) – photosensitizer NAI Acne (BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acne) – peptide elongation factor Tu inhibitor Omiganan (CLS-001; CPI-226; MBI-226; MBI-594AN; MX-226; MX-594AN; Omigard) – antiseptic/antibacterial Pyrilutamide (EX-A5504; HY-145451; KX–826) – antiandrogen (androgen receptor antagonist) Tretinoin topical – retinoid (retinoic acid receptor agonist) VB-1953 – antibiotic and toll-like receptor antagonist
=== Mutation === IDH1 mutations are heterozygous, typically involving an amino acid substitution in the active site of the enzyme in codon 132. These mutations are somatic, meaning they primarily occur in cells that can become cancerous, such as those in brain and bone tumors. The mutation results in a loss of normal enzymatic function and the abnormal production of 2-hydroxyglutarate (2-HG). It has been considered to take place due to a change in the binding site of the enzyme. 2-HG has been found to inhibit enzymatic function of many alpha-ketoglutarate dependent dioxygenases, including histone and DNA demethylases, causing widespread changes in histone and DNA methylation and potentially promoting tumorigenesis.
== Further reading == Becker, Daniel Levin (6 August 2014). "Beaux Absents: On Inventorying What Does not Exit — Review: Works by Édouard Levé Translated by Jan Steyn (Dalkey Archive Press, July 2015)". Retrieved 2 January 2016. Stéphane Girard, Plasticien, écrivain, suicidé. Ethos auctorial et paratopie suicidaire chez Édouard Levé, Paris, L'Harmattan, "Sémantiques", 2014.
On November 20, 2023, all 8 remaining Connecticut Boston Market locations, located in East Haven, Meriden, West Hartford, Wilton, Stratford, Milford, Bristol, and Newington, were permanently shuttered and issued eviction notices due to unpaid rent. Boston Market and owner Pandya filed for Chapter 11 bankruptcy in December 2023. On January 10, 2024, the company announced that it would allow anyone to open a Boston Market franchise without the usual franchise fees or other buy-in requirements. On January 11, 2024, Boston Market's bankruptcy case was dismissed after the company was unresponsive to court requests. On February 1, 2024, US Foods won its lawsuit against Boston Market, with federal judge Manish Shah saying that Boston Market's defenses in the lawsuit were "gossamer". On February 12, 2024, shortly after its second bankruptcy was dismissed, Boston Market filed for bankruptcy for the third time after losing the US Foods lawsuit. On September 24, 2024, a U.S. bankruptcy judge dismissed Boston Market's appeal regarding a $15 million judgement awarded to US Foods, citing a "lack of prosecution" and Pandya's "bad faith," "delay tactics" and "willful disregard".
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.